SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, SriniVas R. Sadda, MD, FARVO, discusses a long-term study evaluating MCO-010 for the treatment of retinitis pigmentosa.
Sadda said patients with retinitis pigmentosa experienced sustained improvements in visual acuity through 126 weeks after treatment with MCO-010 (Nanoscope Therapeutics). Additionally, the safety profile of the gene therapy was favorable, he said.
“There are other optogenetic therapies also under evaluation, which I think reflects the interest in this space,” he said. “MCO-010 is